Organigram Completes €107.3 Million Acquisition of Sanity Group with British American Tobacco Investment
核心洞察
Organigram Global (搜索) finalized its acquisition of Sanity Group (搜索) for €107.3 million, including €78 million in upfront cash and €29.3 million in shares, strengthening its international cannabis operations.
British American Tobacco invested C$65.2 million through a private placement at C$2.72 per share average, demonstrating institutional confidence in Organigram's global expansion strategy.
The transaction was partially funded through Organigram's Jupiter strategic investment pool and a C$60 million senior secured credit facility with ATB Financial (搜索).
Organigram Global (搜索) Inc. (NASDAQ: OGI) has completed its strategic acquisition of Sanity Group (搜索) GmbH for approximately €107.3 million, marking a significant milestone in the Canadian cannabis company's international expansion efforts. The transaction, finalized on April 15, includes €78 million in upfront cash payments and €29.3 million in shares.
Strategic Investment Partnership
The acquisition was supported by a substantial C$65.2 million private placement investment from BT DE Investments (搜索) Inc., a wholly-owned subsidiary of British American Tobacco p.l.c. (LSE: BATs and NYSE: BTI). Under the subscription agreement, BAT purchased 14,027,074 shares at C$3.00 per share for gross proceeds of C$42.08 million, while exercising existing top-up rights for an additional 9,897,356 shares at C$2.335854 per share, generating C$23.12 million in additional proceeds.
The average share price of C$2.72 represents a combination of the top-up rights exercised at C$2.34 per share and new shares issued in connection with the Sanity acquisition priced at C$3.00 per share.
Financing Structure and Ownership Dynamics
A significant portion of the upfront cash payment was financed through Organigram's Jupiter strategic investment pool, established in 2024 specifically to support the company's international growth initiatives. The pool received funding from British American Tobacco, reflecting institutional confidence in Organigram's global expansion strategy.
To maintain regulatory compliance, BAT's ownership structure includes both common shares and non-voting Class A convertible preferred shares. Based on Organigram's 135,132,782 outstanding common shares as of December 31, 2025, BAT received 2,353,379 common shares and 21,571,051 preferred shares through the private placement to stay below the 30% ownership threshold.
The preferred shares feature a unique conversion mechanism, initially convertible on a one-for-one basis with a conversion rate that increases at 7.5% per annum from the initial issuance date. This structure allows BAT to potentially increase its ownership to 49% of outstanding common shares over time while maintaining current regulatory compliance.
Credit Facilities and Transaction Support
Organigram also secured senior secured credit facilities totaling approximately C$60 million through a fully underwritten commitment with ATB Financial (搜索), which served as sole lead arranger and bookrunner. These facilities, combined with the BAT investment and Jupiter fund resources, provided the necessary capital structure to complete the acquisition.
Regulatory Approval and Governance
The transaction required disinterested shareholder approval under Toronto Stock Exchange regulations, as the aggregate shares issued exceeded 25% of Organigram's outstanding shares and the consideration to BAT surpassed 10% of the company's market capitalization. The acquisition and private placement were unanimously approved by Organigram's Board of Directors on February 18, 2026, with BAT's nominees abstaining due to their declared interest.
Under the amended investor rights agreement, BAT maintains the right to nominate up to 30% of Organigram's board members, subject to maintaining certain share ownership thresholds. The company also retains pre-emptive rights, top-up rights, and customary registration rights.
Business Integration and Market Position
Organigram operates as a licensed cannabis cultivator and manufacturer in Canada, with facilities in Moncton, New Brunswick; Lac Supérieur, Quebec; Winnipeg, Manitoba; and two processing facilities in southwestern Ontario. The company's portfolio includes cannabis brands such as Edison, Big Bag O' Buds, SHRED, Monjour, and Trailblazer, serving both medical and recreational adult cannabis markets.
The Sanity Group (搜索) acquisition represents a strategic expansion of Organigram's international footprint, leveraging BAT's global reach and expertise in regulated consumer products. The transaction positions Organigram to capitalize on emerging international cannabis markets while maintaining its strong domestic Canadian operations.